JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Fulgent Genetics Inc

Closed

SectorHealthcare

23.6 0.64

Overview

Share price change

24h

Current

Min

23

Max

23.74

Key metrics

By Trading Economics

Income

-7.4M

-19M

Sales

8.3M

82M

Profit margin

-23.539

Employees

1,313

EBITDA

-3.5M

-15M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+7.79% upside

Dividends

By Dow Jones

Next Earnings

7 lis 2025

Market Stats

By TradingEconomics

Market Cap

181M

730M

Previous open

22.96

Previous close

23.6

News Sentiment

By Acuity

50%

50%

163 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Fulgent Genetics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 paź 2025, 20:49 UTC

Earnings

Correction to Thermo Fisher Article on Oct. 22

23 paź 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 paź 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 paź 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 paź 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 paź 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 paź 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 paź 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 paź 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 paź 2025, 22:17 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 paź 2025, 21:41 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 paź 2025, 21:05 UTC

Earnings

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 paź 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

23 paź 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

23 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 paź 2025, 20:35 UTC

Earnings

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 paź 2025, 20:28 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 paź 2025, 20:15 UTC

Market Talk
Earnings

Global Commodities Roundup: Market Talk

23 paź 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Adj EPS $1.71

23 paź 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Sales $5.52B

23 paź 2025, 20:10 UTC

Earnings

Newmont Mining 3Q EPS $1.67

23 paź 2025, 20:09 UTC

Earnings

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 paź 2025, 20:07 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

23 paź 2025, 20:07 UTC

Market Talk
Earnings

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 paź 2025, 20:07 UTC

Earnings

Blackstone Looks to IPOs for Investment Exits -- Update

23 paź 2025, 20:05 UTC

Earnings

Intel 3Q Gross Margin 38.2% >INTC

23 paź 2025, 20:04 UTC

Earnings

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 paź 2025, 20:04 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 paź 2025, 20:04 UTC

Earnings

Intel: 4Q Guidance Excludes Altera >INTC

23 paź 2025, 20:04 UTC

Earnings

Intel Sees 4Q Adj EPS 8c >INTC

Peer Comparison

Price change

Fulgent Genetics Inc Forecast

Price Target

By TipRanks

7.79% upside

12 Months Forecast

Average 25.33 USD  7.79%

High 30 USD

Low 21 USD

Based on 3 Wall Street analysts offering 12 month price targets forFulgent Genetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

17.32 / 19.04Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

163 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat